NasdaqGS - Nasdaq Real Time Price USD

Syros Pharmaceuticals, Inc. (SYRS)

5.10 +0.03 (+0.59%)
At close: April 25 at 4:00 PM EDT
5.10 0.00 (0.00%)
Pre-Market: 7:00 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
9,936.00
9,936.00
14,880.00
23,488.00
15,093.00
Operating Expense
136,435.00
136,435.00
141,243.00
122,908.00
97,390.00
Operating Income
-126,499.00
-126,499.00
-126,363.00
-99,420.00
-82,297.00
Net Non Operating Interest Income Expense
1,689.00
1,689.00
-2,002.00
-3,820.00
-1,366.00
Other Income Expense
-39,764.00
-39,764.00
33,711.00
16,682.00
-375.00
Pretax Income
-164,574.00
-164,574.00
-94,654.00
-86,558.00
-84,038.00
Net Income Common Stockholders
-164,574.00
-164,574.00
-94,654.00
-86,558.00
-84,038.00
Diluted NI Available to Com Stockholders
-164,574.00
-164,574.00
-94,654.00
-86,558.00
-84,038.00
Basic EPS
-5.81
-5.81
-7.49
-13.84
-18.20
Diluted EPS
-5.81
-5.81
-7.49
-13.84
-18.20
Basic Average Shares
28,325.78
28,325.78
12,631.97
6,253.50
4,605.16
Diluted Average Shares
28,325.78
28,325.78
12,631.97
6,253.50
4,605.16
Total Operating Income as Reported
-128,988.00
-128,988.00
-135,873.00
-99,420.00
-82,297.00
Total Expenses
136,435.00
136,435.00
141,243.00
122,908.00
97,390.00
Net Income from Continuing & Discontinued Operation
-164,574.00
-164,574.00
-94,654.00
-86,558.00
-84,038.00
Normalized Income
-124,810.00
-124,810.00
-128,365.00
-103,240.00
-83,663.00
Interest Income
6,816.00
6,816.00
2,132.00
87.00
426.00
Interest Expense
5,127.00
5,127.00
4,134.00
3,907.00
1,792.00
Net Interest Income
1,689.00
1,689.00
-2,002.00
-3,820.00
-1,366.00
EBIT
-159,447.00
-159,447.00
-90,520.00
-82,651.00
-82,246.00
EBITDA
-157,195.00
-157,195.00
-87,814.00
-79,633.00
-79,211.00
Reconciled Depreciation
2,252.00
2,252.00
2,706.00
3,018.00
3,035.00
Net Income from Continuing Operation Net Minority Interest
-164,574.00
-164,574.00
-94,654.00
-86,558.00
-84,038.00
Total Unusual Items Excluding Goodwill
-39,764.00
-39,764.00
33,711.00
16,682.00
-375.00
Total Unusual Items
-39,764.00
-39,764.00
33,711.00
16,682.00
-375.00
Normalized EBITDA
-117,431.00
-117,431.00
-121,525.00
-96,315.00
-78,836.00
12/31/2020 - 6/30/2016

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

SYRE Spyre Therapeutics, Inc.
32.47
-1.58%
 
FGEN FibroGen, Inc.
1.0200
+3.63%
 
GLYC GlycoMimetics, Inc.
1.7100
-7.82%
 
KURA Kura Oncology, Inc.
19.00
+1.33%
 
ADAP Adaptimmune Therapeutics plc
1.0600
-1.85%
 
ACIU AC Immune SA
2.2900
-3.38%
 
BDTX Black Diamond Therapeutics, Inc.
5.11
+0.99%
 
MCRB Seres Therapeutics, Inc.
0.7427
+1.81%
 
MAIA MAIA Biotechnology, Inc.
2.6800
-0.37%
 
STRO Sutro Biopharma, Inc.
3.4200
-1.44%